The company, which is collaborating with Myeloma Crowd, will use the newly-licensed minicircle DNA technology to develop therapies for multiple myeloma.
International research teams collaborated to create five fully functioning synthetic yeast chromosomes, taking them one step closer to a whole synthetic genome.
The collaborators hope initial research in canines can be a proving ground for synthetic viruses designed to kill particular tumors, perhaps even in humans.
